glp-1 houston Semaglutide Weight Loss GLP-1 Therapy for Weight Loss
Description
Phase 4

The UK reimburses GLP-1s for obesity but with much stricter requirements than label indications: BMI 35 plus at least one weight-related comorbidity

The first indication was provided by a small, pilot study in patients with diabetes

It could potentially also cause serotonin syndrome, a serious condition resulting from high serotonin levels

New and World Report
Never double up on doses, and consult your patient information leaflet for specific guidance
